Startup
TPThe Phage
Develops CGFM, a foundation model trained on continuous blood-glucose data to predict post-meal glucose swings; capital and business alliance with Tokio Marine.
Funding rounds
Grey amounts aren't counted in totals. † includes debt or other non-equity.
| Date | Company | Stage | Amount | Investors | Sector |
|---|---|---|---|---|---|
| 9 Oct 2026 | TPThe Phage | Series A | ¥570M† | See source | Healthcare |